
April 26 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON'S TAR-200 MONOTHERAPY DEMONSTRATES HIGHEST COMPLETE RESPONSE RATE WITH SUSTAINED CLINICAL BENEFITS IN PATIENTS WITH CERTAIN TYPES OF BLADDER CANCER
JOHNSON & JOHNSON - PHASE 2B STUDY: 82% ACHIEVE COMPLETE RESPONSE, 52.9% CANCER-FREE AT ONE YEAR
JOHNSON & JOHNSON - TAR-200 POTENTIAL TO TRANSFORM OUTCOMES FOR BCG-UNRESPONSIVE BLADDER CANCER
JOHNSON & JOHNSON - INITIATES FDA APPLICATION FOR TAR-200 UNDER RTOR PROGRAM